14. Initial results of total neoadjuvant therapy with short course radiotherapy followed by chemotherapy for stage II, III rectal cancer
Main Article Content
Abstract
The descriptive study aimed to assess the initial results in 71 patients with stage II, III rectal cancer at Hanoi Oncology Hospital, K Hospital, and 108 Military Central Hospital from August 2023 to January 2025. Patients received total neoadjuvant therapy using short-course radiotherapy (25 Gy) followed by CAPEOX or mFOLFOX6 chemotherapy, and subsequent surgery. 94.4% of patients completed the chemotherapy regimen. The rate of sphincter-preserving surgery was 79.7% and 57.1% for low rectal cancer. The pathological complete response rate was 33.3%. The most common acute adverse effects were thrombocytopenia and elevated liver enzymes, mostly grade 1, 2 and with no deathreported. These initial results suggest that total neoadjuvant therapy using short-course radiotherapy followed by chemotherapy in patients for stage II and III rectal cancer results a high pathological complete response rate, acceptable toxicity, and good treatment adherence.
Article Details
Keywords
Rectal cancer, total neoadjuvant therapy, short-course radiotherapy, pathological complete response
References
2. K Bujko, M P Nowacki, A Nasierowska-Guttmejer, W Michalski, M Bebenek, M Kryj. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. British Journal of Surgery. Volume 93, Issue 10, October 2006, Pages 1215-1223, https://doi.org/10.1002/bjs.5506.
3. Ali F, Keshinro A, Weiser MR. Advances in the treatment of locally advanced rectal cancer. Ann Gastroenterol Surg. 2020; 5(1): 32-38. Published 2020 Aug 30. doi:10.1002/ags3.12389.
4. Kim SH, Chang HJ, Kim DY, et al. What Is the Ideal Tumor Regression Grading System in Rectal Cancer Patients after Preoperative Chemoradiotherapy?. Cancer Res Treat. 2016; 48(3): 998-1009. doi:10.4143/crt.2015.254.
5. Phạm Khánh Toàn, Võ Văn Xuân. Đánh giá kết quả hóa xạ trị tiền phẫu ung thư trực tràng bằng kỹ thuật VMAT kết hợp Capecitabine đường uống tại bệnh viện K. Tạp chí Y học Việt Nam. 2021; số 1-2021: tr. 261 https://doi.org/10.51298/vmj.v509i1.1750.
6. Nguyễn Hải Hoàng, Bùi Quang Biểu, Vũ Hồng Thăng. Kết quả bước đầu hóa xạ trị đồng thời kết hợp hóa trị bổ trợ trước phẫu thuật bệnh nhân ung thư trực tràng giai đoạn II, III. Tạp Chí Nghiên cứu Y học. 2024; 179(6), 166-174. https://doi.org/10.52852/tcncyh.v179i6.2489.
7. Jin J, Tang Y, Hu C, et al. Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR). J Clin Oncol. 2022; 40(15): 1681-1692. doi:10.1200/JCO.21.01667.
8. Bahadoer RR, Dijkstra EA, van Etten B, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial [published correction appears in Lancet Oncol. 2021 Feb; 22(2): e42. doi: 10.1016/S1470-2045(20)30781-6.]. Lancet Oncol. 2021; 22(1): 29-42. doi:10.1016/S1470-2045(20)30555-6.
9. Conroy T, Bosset JF, Etienne PL, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021; 22(5): 702-715. doi:10.1016/S1470-2045(21)00079-6.
10. Chakrabarti D, Rajan S, Akhtar N, et al. Short-course radiotherapy with consolidation chemotherapy versus conventionally fractionated long-course chemoradiotherapy for locally advanced rectal cancer: randomized clinical trial. Br J Surg. 2021; 108(5): 511-520. doi:10.1093/bjs/znab020.